Work

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis

Year: 2023

Type: article

Abstract: New meta-analyses are presented that provide further evidence supporting the effectiveness of oral prolonged-release mesalazine compared to other oral mesalazines as induction therapy in patients with moderately active ulcerative colitis.

Source: JGH Open

DOI: 10.1002/jgh3.12935

Authors: Kristine Paridaens, John R Fullarton, Simon P L Travis

Institutions: Ferring Pharmaceuticals (Switzerland), John Radcliffe Hospital, NIHR Oxford Biomedical Research Centre

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,200

Funders: Eli Lilly and Company, Pfizer, Celgene, Ferring

OpenAlex ID: W4383552273

FWCI: 1.449

Cites: 15

Cited by: 8

Related to: 10